Egyszerű nézet

dc.contributor.author Iqbal, Amna
dc.contributor.author Malik, Shahrukh
dc.contributor.author Nurulain, Syed M
dc.contributor.author Musilek, Kamil
dc.contributor.author Kuca, Kamil
dc.contributor.author Kalász, Huba
dc.contributor.author Fatmi, M Qaiser
dc.date.accessioned 2021-12-10T08:52:58Z
dc.date.available 2021-12-10T08:52:58Z
dc.date.issued 2019
dc.identifier.citation journalVolume=310;pagination=108735, pages: 9;journalTitle=CHEMICO-BIOLOGICAL INTERACTIONS.;journalAbbreviatedTitle=CHEMICO-BIOL INTERACT.;
dc.identifier.uri http://repo.lib.semmelweis.hu//handle/123456789/8133
dc.identifier.uri doi:10.1016/j.cbi.2019.108735
dc.description.abstract Organophosphates (OPs) irreversibly inhibit acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) enzymes. The reactivation of these inhibited enzymes is paramount for their normal function. Present study evaluates reactivation potency of two newly developed oximes, K456 and K733, against paraoxon (POX)-inhibited human-RBC-AChE and human-plasma-BChE in comparison to reported reactivator, pralidoxime (2-PAM). In vitro studies showed higher intrinsic toxicities of both oximes than 2-PAM for AChE. No substantial reactivation of BChE was noted by tested concentration. Contrary to 2-PAM, the in silico study predicted lower binding free energies for both oximes. However, the detailed interaction study revealed inability of oximes to interact with catalytic anionic site of AChE and BChE in contrast to 2-PAM. Both in vitro and in silico studies conclude that K456 and K733 are unlikely to be used as reactivators of paraoxon-inhibited AChE or BChE.
dc.relation.ispartof urn:issn:0009-2797
dc.title Reactivation potency of two novel oximes (K456 and K733) against paraoxon-inhibited acetyl and butyrylcholinesterase
dc.type Journal Article
dc.date.updated 2020-01-13T15:42:52Z
dc.language.rfc3066 en
dc.rights.holder NULL
dc.identifier.mtmt 30732516
dc.identifier.wos 000482179600019
dc.identifier.pubmed 31276662
dc.contributor.department SE/AOK/I/Farmakológiai és Farmakoterápiás Intézet
dc.contributor.institution Semmelweis Egyetem


Kapcsolódó fájlok:

A fájl jelenleg csak egyetemi IP címről érhető el.

Megtekintés/Megnyitás

Ez a rekord az alábbi gyűjteményekben szerepel:

Egyszerű nézet